Macrophage Nanosponge (MΦ-NS)
Macrophages are the foundation of our immune systems. They surround and kill microorganisms, remove dead cells, and can even stimulate the action of other immune system cells. When macrophages are activated by foreign microorganisms such as bacteria and viruses that enter the human body, they release molecules known as cytokines, which can activate more macrophages and stimulate further immune response and cause inflammation. Severe viral or bacterial infections could cause macrophages to over-respond and cause serious systemic inflammation such as cytokine storm or sepsis.
We craft tens of thousands of MΦ-NS from just one macrophage. The MΦ-NS is a powerful advancement in nanomedicine, with versatile applications. On one hand, the MΦ-NS can effectively absorb and neutralize inflammatory cytokines and control inflammation, used to treat diseases such as Sepsis and Cytokine Release Syndrome (CRS). On the other hand, the Macrophage Nanosponge can also be made into oral, topical, or intraarticular formulations to treat inflammatory diseases such as Inflammatory Bowel Disease and Arthritis.
Cellics’ drug candidate CTI-111 is for the treatment of sepsis and has received funding from CARB-X. This important partnership with CARB-X allows Cellics to advance its highly versatile platform to treat not only sepsis but other conditions with unmet medical needs such as post CAR-T Cytokine Release Syndrome (CRS).